Roivant Cuts Multiple R&D Programs As It Takes On Pfizer’s TYK2/JAK1 Inhibitor

Sickle Cell, Dermatology And Cancer Drugs Among Discontinued Assets

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Roivant and Pfizer launched Priovant to develop the oral drug brepocitinib for dermatomyositis, lupus and other autoimmune diseases, but Roivant also cut programs to extend its cash runway.

Digital money send, currency exchange sign. Neon futuristic transfer arrow icon. Web trade symbol. Mutual exchange of information isolated on blue background
Roivant swapped out multiple programs to conserve cash and bring in a late-stage Pfizer asset • Source: Shutterstock

Roivant Sciences Ltd. and Pfizer Inc. officially launched Priovant Therapeutics on 28 June to develop Pfizer’s TYK2/JAK1 inhibitor brepocitinib, but the companies had been working together since September 2021 on plans for advancing the oral drug, initially for the treatment of dermatomyositis and system lupus erythematosus (SLE) and eventually for additional autoimmune diseases with high morbidity and mortality and limited treatment options.

Roivant CEO Matt Gline described the agreement with Pfizer as “a capital-efficient deal for us” during the company’s same-day call...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.